Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Pharma park to come up at Chanho, says Jharkhand Govt

Ruchika Sharma14 Sept 2021 2:27 PM IST

Ranchi: The Jharkhand government on Monday said it is setting up a dedicated Pharma Park at Chanho near here to attract investment in the sector.The...

Banking on dengue, COVID-19 shots progress, Takeda CEO eyes vaccine business growth

Ruchika Sharma14 Sept 2021 12:00 PM IST

Tokyo: Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its...

ICPA introduces 'Wet Mouth' - Saliva Substitute For Individuals Suffering From Dry Mouth

Ruchika Sharma14 Sept 2021 11:00 AM IST

Mumbai: ICPA Health Products Ltd (ICPA) has recently introduced Wet Mouth, a saliva substitute for treating individuals suffering from xerostomia or...

PharmEasy parent appoints 5 independent directors

Ruchika Sharma13 Sept 2021 4:04 PM IST

New Delhi: API Holdings, the parent company of PharmEasy, on Monday said it has appointed five independent directors to its Board.The fresh...

Pfizer COVID vaccine for kids aged 12, above approved in South Africa

Ruchika Sharma13 Sept 2021 3:56 PM IST

Johannesburg: South Africa's health regulator has approved Pfizer's COVID-19 vaccine for use by children aged 12 and older, paving the way for the...

First: Antioxidant gamma oryzanol launched in India as vegetarian capsule

Ruchika Sharma13 Sept 2021 2:50 PM IST

New Delhi: With the outbreak of the COVID-19 pandemic making people aware about the importance of maintaining a healthy lifestyle and developing a...

COVID: WHO seeks more data from Sputnik V makers to grant emergency Use Listing

Ruchika Sharma13 Sept 2021 1:31 PM IST

New Delhi: The World Health Organisation has sought some more data from Russia's Gamaleya National Research Institute of Epidemiology and...

Granules India, Jubilant Cadista recall products in US

Ruchika Sharma13 Sept 2021 1:23 PM IST

New Delhi: Generic drug makers Granules India and Jubilant Cadista are recalling different products in the US, the world's largest market for...

Atleast 2 billion COVID vaccine doses to be available in 2022: Novavax

Ruchika Sharma12 Sept 2021 10:30 AM IST

New Delhi: Vaccine developer Novavax Inc said on Friday at least 2 billion doses of its COVID-19 vaccine would be available in 2022.The company,...

Moderna, Resilience tie up to manufacture mRNA for COVID vaccine

Ruchika Sharma12 Sept 2021 10:15 AM IST

Cambridge: Moderna, Inc. and National Resilience, Inc. have recently announced an agreement to manufacture drug substance for the Moderna...

Roche to acquire TIB Molbiol Group to expand PCR-test portfolio against infectious diseases

Ruchika Sharma12 Sept 2021 10:00 AM IST

Basel: Roche has recently announced that the company has signed a definitive share purchase agreement to acquire 100% of the outstanding shares of the...

USFDA accepts Pfizer, Myovant MYFEMBREE review application to treat endometriosis linked pain

Ruchika Sharma12 Sept 2021 9:30 AM IST

Basel: Pfizer Inc. and Myovant Sciences have announced that the U.S. Food and Drug Administration (FDA) has accepted for review a...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok